Loading...
Rucaparib and Niraparib in Advanced Ovarian Cancer
Rucaparib and niraparib are two of the newest U.S. Food and Drug Administration–approved PARP inhibitors, joining olaparib with indications in ovarian cancer. Both drugs have led to meaningful responses when used as monotherapy in previously treated ovarian cancers, with niraparib demonstrating acti...
Saved in:
| Published in: | J Adv Pract Oncol |
|---|---|
| Main Author: | |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Harborside Press LLC
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7520743/ https://ncbi.nlm.nih.gov/pubmed/33343988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.4.8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|